Microneedle Drug Delivery Systems to 2020
|発行||Greystone Research Associates||商品コード||250428|
|マイクロニードルドラッグデリバリーシステム 2020年 Microneedle Drug Delivery Systems to 2020|
|出版日: 2015年12月01日||ページ情報: 英文||
当レポートでは、マイクロニードルドラッグデリバリー市場について取り上げ、マイクロニードルデバイス・システムに提供されている認可薬、デバイスの仕様、および販売者、マイクロニードルドラッグデリバリーデバイス・システムのサプライヤーとその製造インフラ、ロケーションおよび能力、マイクロニードルドラッグデリバリーの需要影響因子、マイクロニードルの設計 & 技術、およびマイクロニードルデリバリー製品の重要な治療市場とその市場シェアなどについて調査分析しています。
Microneedle technology is attaining commercial viability at a time when drug developers are faced with new challenges as they assess ways to administer new classes of compounds with significant therapeutic potential. The widespread availability of rapid throughput screening is accelerating the discovery of new drugs, a significant number of which are large-molecule therapeutic compounds that cannot tolerate passage through the digestive system, requiring pharmaceutical companies to forego oral formulations and select alternate routes of administration. Microneedle technology has the potential address the growing trend toward self-administration by allowing the precise placement of therapeutic agents at prescribed locations below the skin. To succeed, developers must refine the techniques for large-scale manufacturing and advance the design integration of microneedles into commercially viable drug delivery systems.
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
‘Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered. This trend is being fostered by the desire by patients for more user friendly methods for self-medicating, and by the need for safer, more reliable drug products that improve compliance. For drugs capable of being administered across the skin, intradermal delivery is viewed as an approach that addresses these key healthcare objectives. Intradermal delivery offers several advantages when compared to alternative technologies, including being minimally invasive and inducing minimal trauma during delivery.'